Case 33 Repligen

Repligen Corporation is a global life science company which develops and commercializes highly innovative bioprocessing technologies and systems which facilitate the manufacturing of biological drugs. Repligen was founded in the year 1981 by two distinguished scientists Prof Alexander Rich and Prof Paul Schimmel who pioneered breakthrough advances in the field of molecular biology. Repligen offers a comprehensive suite of products in its bioprocessing business which are used for upstream and downstream processes in biological drug manufacturing. The product portfolio offered by Repligen consists of filtration, chromatography, process analytics, and proteins. The proteins business focuses on affinity ligands and growth factor solutions. The growth strategy basically aims for expansion of geographic scope, customer base, and application of technologies. An amount of $1000 invested in Repligen share in 2003 would have amounted to $58,270 by 2023 representing total return of 5728%. The total revenues and net income grew by 49% and 70% respectively during the period 2017–2021.